Randomized Trialhigh evidence
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
JAMA·July 13, 2026·PMID 42441396
Why it mattersOGA inhibition remains a biologically plausible target for reducing tau pathology in Alzheimer disease, but this well-powered trial found no clinical efficacy for ceperognastat, tempering expectations for this mechanism in early symptomatic stages.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled